Clinical analysis for the prognostic factors in patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery.
10.3802/kjgo.2008.19.1.75
- Author:
Hee Seung KIM
1
;
Tae Hun KIM
;
Hyun Hoon CHUNG
;
Jae Weon KIM
;
Noh Hyun PARK
;
Yong Sang SONG
;
Soon Beom KANG
Author Information
1. Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. kjwksh@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Secondary cytoreductive surgery;
Prognostic factor;
Recurrent;
Epithelial ovarian cancer
- MeSH:
Chemotherapy, Adjuvant;
Disease-Free Survival;
Humans;
Neoplasm, Residual;
Neoplasms, Glandular and Epithelial;
Ovarian Neoplasms;
Reference Values;
Retrospective Studies;
Seeds
- From:Korean Journal of Gynecologic Oncology
2008;19(1):75-80
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To identify clinical prognostic factor improving survival of recurrent epithelial ovarian cancer (EOC) patients treated with secondary cytoreductive surgery (SCS). METHODS: The indications of SCS were as follows; 1) complete response (CR) after primary cytoreductive surgery and adjuvant chemotherapy, 2) disease-free survival (DFS) (> or =6 months). Clinical data of 17 patients including age, DFS, peritoneal seeding identified during SCS, the number of recurrent tumors (> or =1 cm), serum CA-125 levels and maximal diameter of residual tumor after SCS were reviewed retrospectively between January 1990 and March 2007. Survival analyses were performed using Kaplan-Meier method with log-rank test and univariate Cox's regression analysis. RESULTS: Mean age of them was 51.7 years. No peritoneal seeding identified during SCS was a prognostic factor improving progression-free survival after SCS (PFS-SCS) (30 vs. 6 months, p<.01 hazard ratio 0.099, 95% confidence interval 0.011-0.929, p=.043). Furthermore, serum CA-125 level (< or =37 U/ml) after SCS was a significant prognostic factors improving overall survival (51 vs. 19 months, p=.033; hazard ratio 0.212, 95% confidence interval 0.045-0.983, p=.045). CONCLUSION: Serum CA-125 levels with normal value after SCS and no peritoneal seeding may be associated with the improvement of survival in recurrent epithelial ovarian cancer patients treated with SCS.
